Annovis is attempting to lessen α-synuclein-induced pathogenesis by reducing the synthesis of the α-synuclein protein.
PNT article: First Patients Dosed in Clinical Trial Investigating ANVS401 as Treatment for Parkinson’s and Alzheimer’s
parkinsonsnewstoday.com/202...
Trial Record: Posiphen Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
clinicaltrials.gov/ct2/show...
SoPD blog post (background info): Disney’s “Attack of the synucleozid from Jupiter”
scienceofparkinsons.com/202...
Posiphen (ANVS401) mode of action:
Posiphen is an orally available small molecule drug that inhibits the translation of α-synuclein, by increasing the affinity of Iron Regulatory Protein-1 (IRP1) to the Iron-Response Element (IRE) of the SNCA gene's messenger RNA (mRNA). This represses translation by preventing the association of the mRNA with the ribosome.
Parkinson's Disease: emerging treatment target, the NLRP inflammasome. 
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Clinical Trial Accepting Now
